This trial is evaluating whether Ibrutinib will improve 2 primary outcomes and 3 secondary outcomes in patients with Stage IIIB Cutaneous Melanoma AJCC v7. Measurement will happen over the course of Up to start of second course of treatment.
This trial requires 23 total participants across 1 different treatment group
This trial involves a single treatment. Ibrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The signs and symptoms of melanoma are variable in number and intensity, often appearing and disappearing rapidly. Allowing an open mind and regular observation for melanoma is vital and can contribute to early diagnosis and improved prognosis for these conditions." - Anonymous Online Contributor
"There has been a dramatic increase in the worldwide incidence of melanoma in recent years (increasing more than fivefold between 1976 and 1998). A majority (70%) of patients are diagnosed with Stage I disease, which carries a median survival of up to 10 years. Overall 5-year and 10-year mortality are 24% and 49%, respectively. Tumor thickness and lymph node evaluation are strong indicators of outcome. Overall 5-year and 10-year survival in the US are 85% and 53%, respectively. Current staging practices differ from those used in earlier studies because of a lack of consensus regarding whether staging should occur in all patients, or only in subset patients." - Anonymous Online Contributor
"Results from a recent clinical trial highlights the complexity of the tumour-microenvironment interactions. It highlights the need for the development of adjuvant vaccines to treat Stage IV and metastatic melanoma." - Anonymous Online Contributor
"We estimate roughly 70,000 new cases of melanoma will be diagnosed in the U.S. in 2017. Melanoma is currently one of the most deadly, but non-communicable, cancers in the United States. Because melanoma-related deaths are highly preventable, our data highlight the urgent need for better and more accurate tools for monitoring melanoma incidence." - Anonymous Online Contributor
"Melanoma is caused by abnormal pigmentation of the skin, more specifically the formation of melanin pigment in the epidermal layer of the skin. It is more likely in men than women and starts on sun-exposed areas of the skin later in life. There is also a genetic predisposition to melanoma. There is evidence that exposure to ultraviolet light between the ages of 15–59 prevents melanoma during a person's lifetime in the absence of other, unrelated factors. The risk of developing melanoma can be reduced by avoiding sun exposure, UV-protection clothing and the use of sunscreen with a SPF no lower than 30." - Anonymous Online Contributor
"Treatments for melanoma are dependent on several factors which must be considered when determining management. Common treatments include surgery, radiation, topical agents, chemotherapy, immunotherapy and immunobiology." - Anonymous Online Contributor
"(1) Ibrutinib (brand name Ikblis) is an effective anti-cancer agent for patients with advanced phase III-resistant or refractory mantle cell lymphoma (MCL) in the second-line setting. (2) Ibrutinib produced durable responses in patients who had received one or more previous therapies for MCL and advanced stage III chronic lymphocytic leukemia (CLL). (3) Ibrutinib was associated with favorable safety and tolerability. Findings from a recent study support further exploration of ibrutinib in second-line treatment of MCL." - Anonymous Online Contributor
"After a long period of declining incidence trends, an upward trend in incidence is expected to continue for the next 10 years. In order to improve screening programs, more efforts should be made to increase awareness of melanoma disease and promotion of detection programs." - Anonymous Online Contributor
"Patient education regarding the value of early detection, particularly of moles, combined with a balanced appraisal of the level of evidence linking treatment to survival and the relative benefits and risks of treatment, constitute important considerations for clinicians when making their decisions about patient eligibility for clinical trials. The role of clinical trials as a valid tool to determine the best management approach for individuals with malignant melanoma warrants further investigation, and a high-quality, adequately designed, prospective trial comparing current management with new agents and/or treatment modalities would represent a valuable contribution to the knowledge needed to optimize therapy for this disease." - Anonymous Online Contributor
"ibrutinib was safe and well tolerated in patients with advanced solid tumors including non-small cell lung cancers. The FDA approval of ibrutinib in the first-line treatment of patients with chronic lymphocytic leukemia can advance the treatment of patients with solid tumors, including non-small cell lung cancers." - Anonymous Online Contributor
"In vitro, ibrutinib inhibited the growth of both erythroleukemia and melanoma by inducing differentiation of erythroleukemia cells through erythropoietin-independent mechanisms. These antitumor effects were not enhanced by c-Kit/FGF signaling pathway inhibition, suggesting the applicability of ibrutinib for CLL by targeting the erythropoietin pathway in vitro." - Anonymous Online Contributor
"Melanoma run through families, but whether genetic or environmental, neither can explain the rarity of familial melanoma. The high prevalence and the relatively young age profile of melanoma in Caucasian family members and siblings strongly suggest an inherited genetic etiology instead." - Anonymous Online Contributor